Retatrutide (sodium salt)

Formulation: A solid

Formal Name: L-tyrosyl-2-methylalanyl-L-glutaminylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-tyrosyl-L-seryl-L-isoleucyl-2-methyl-L-leucyl-L-leucyl-L-α-aspartyl-L-lysyl-N6-[N-(19-carboxy-1-oxononadecyl)-L-γ-glutamyl-2-[2-(2-aminoethoxy)ethoxy]acetyl]-L-lysyl-L-alanyl-L-glutaminyl-2-methylalanyl-L-alanyl-L-phenylalanyl-L-isoleucyl-L-α-glutamyl-L-tyrosyl-L-leucyl-L-leucyl-L-α-glutamylglycylglycyl-L-prolyl-L-seryl-L-serylglycyl-L-alanyl-L-prolyl-L-prolyl-L-prolyl-L-serinamide, sodium salt

Purity: ≥98%

Formula Markup: C221H342N46O68 • XNa

Formula Weight: 4731,3

Shelf life (days): 1460

Notes: Retatrutide is a triple agonist of the glucagon receptor (GCGR), glucagon-like peptide 1 receptor (GLP-1R), and gastric inhibitory polypeptide receptor (GIP receptor), also known as the glucose-dependent insulinotropic polypeptide receptor.{67718} It induces cAMP accumulation in HEK293 cells expressing the human GCGR, GLP-1R, or GIP receptor (EC50s = 5.79, 0.775, and 0.0643 nM, respectively). Retatrutide (0.1-30 nmol/kg) decreases plasma glucose levels in an intraperitoneal glucose tolerance test in mice. It decreases body weight, calorie intake, fat mass, and lean mass in a mouse model of diet-induced obesity in a dose-dependent manner. Acute administration of retatrutide (10 nmol/kg) delays gastric emptying and chronic administration for 10 days decreases food intake and body weight in mice.{67719}

• Artikelnummer: CAY39747-5
• Hersteller: Cayman Chemical
• Hersteller Artikelnummer: 39747-5
• Verpackungseinheit: 5 mg
• Mengeneinheit: STK